Bildkälla: Stockfoto

Xspray Pharma: Good News From The FDA - Redeye

Redeye is left feeling encouraged following the news that the FDA has, following its initial review, agreed to conduct a comprehensive review of the Dasynoc application under the 505(b)(2) process.

Redeye is left feeling encouraged following the news that the FDA has, following its initial review, agreed to conduct a comprehensive review of the Dasynoc application under the 505(b)(2) process.
Börsvärldens nyhetsbrev
ANNONSER